TACE With Thermosensitive Nanogel Versus Embosphere for HCC

StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated September 19, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhongda Hospital
44 trials monitored
See 2 trials at risk
Liver Cancer
1,602 trials monitored
See 70 trials at risk
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Trial Details
NCT Number NCT06593964
Lead Sponsor Zhongda Hospital
Conditions
(from sponsor)		 Unresectable Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov